**Summary**
Schroders Capital Global Innovation Trust plc (the Company) announced its final results for the year ended 31 December 2025, highlighting its managed wind-down strategy and capital returns to shareholders. Key points include
1. **Managed Wind-Down** Following shareholder approval, the Company focused on an orderly wind-down, realizing portfolio assets while balancing timely returns and value maximization.
2. **Capital Returns**
Completed a £37 million tender offer in July 2025.
Plans a further £18 million tender offer in June 2026, subject to shareholder approval.
3. **Financial Performance**
NAV per share increased by 11.5% to 22.23p.
Share price rose by 38.2% to 15.20p.
Total realisations of £35.9 millionincluding sales of Araris BiotechSecuriti AIand Anthos Therapeutics.
4. **Portfolio Highlights**
Life sciences portfolio drove performance, with Araris sale generating £18.0 million in gains.
Growth portfolio contributed positively, with valuation uplifts for AI Company II and Revolut.
5. **Post-Year Developments**
Received £6.5 million from the sale of Bluewater Bio in January 2026.
No material realisations expected before 2028.
6. **Board and Governance**
Reduced board size to three directors post-wind-down approval.
AGM scheduled for 2 June 2026, with a concurrent General Meeting for tender offer approval.
7. **Outlook**
Focus remains on disciplined asset realisation and liquidity management.
Increased volatility expected as the portfolio becomes more concentrated.
The Company continues to prioritize shareholder returns and transparency during its wind-down phase.